| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM.1902 |
| P8608 | Fatcat ID | release_7bndod4mbneglhfadrfvzbkvlu |
| P698 | PubMed publication ID | 19122656 |
| P5875 | ResearchGate publication ID | 23720337 |
| P50 | author | Markus H Heim | Q39188870 |
| Witold Filipowicz | Q62559799 | ||
| Magdalena Sarasin-Filipowicz | Q114422800 | ||
| P2093 | author name string | Jacek Krol | |
| Ilona Markiewicz | |||
| P2860 | cites work | Cellular cofactors affecting hepatitis C virus infection and replication | Q24317564 |
| miRBase: tools for microRNA genomics | Q24649872 | ||
| Interferon signaling and treatment outcome in chronic hepatitis C | Q27486083 | ||
| Interferon modulation of cellular microRNAs as an antiviral mechanism | Q27489711 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
| LNA-mediated microRNA silencing in non-human primates | Q29615962 | ||
| Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state | Q45872960 | ||
| Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. | Q50570121 | ||
| Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. | Q50579007 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| microRNA | Q310899 | ||
| P304 | page(s) | 31-33 | |
| P577 | publication date | 2009-01-04 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy | |
| P478 | volume | 15 |
| Q35860325 | A cross-talk between Hepatitis B virus and host mRNAs confers viral adaptation to liver |
| Q39188886 | A double-switch vector system positively regulates transgene expression by endogenous microRNA expression (miR-ON vector). |
| Q34553883 | Adenosine deaminases acting on RNA, RNA editing, and interferon action. |
| Q34039791 | An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones |
| Q35120813 | Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. |
| Q34108902 | Antagonizing microRNA-122 and treatment of hepatitis C virus infection |
| Q34108728 | Antisense gets a grip on miR-122 in chimpanzees |
| Q37461841 | BRCA1 and microRNAs: emerging networks and potential therapeutic targets |
| Q37514366 | Cellular and molecular biology of HCV infection and hepatitis |
| Q35069646 | Cellular microRNA miR-181b inhibits replication of mink enteritis virus by repression of non-structural protein 1 translation |
| Q64240551 | Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir |
| Q44824138 | Characterization of microRNA expression profiles associated with hepatitis B virus replication and clearance in vivo and in vitro |
| Q37086191 | Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels |
| Q34486635 | Circulating RNA molecules as biomarkers in liver disease |
| Q28533876 | Circulating liver-specific miR-122 as a novel potential biomarker for diagnosis of cholestatic liver injury |
| Q45194892 | Circulating miR-122 as a potential biomarker of liver disease |
| Q35628167 | Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C. |
| Q34009053 | Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease |
| Q39498041 | Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis |
| Q54394432 | Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. |
| Q42188218 | Clinical significance of intragraft miR-122 and -155 expression after liver transplantation |
| Q34302987 | Complex interactions between microRNAs and hepatitis B/C viruses |
| Q33492595 | Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers |
| Q39681139 | Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. |
| Q35156115 | Correlation of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2 expression and angiogenic factors in cirrhotic and noncirrhotic human hepatocellular carcinoma |
| Q30381336 | Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic. |
| Q42267958 | Decreased level of intracellular cholesterol in peripheral blood mononuclear cells is associated with chronic hepatitis C virus infection |
| Q59350656 | Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5 |
| Q21245110 | Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha |
| Q45352623 | Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation |
| Q47393235 | Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation. |
| Q42110018 | Dual Role of miR-122 in Molecular Pathogenesis of Viral Hepatitis |
| Q35262563 | Dual regulation of hepatitis C viral RNA by cellular RNAi requires partitioning of Ago2 to lipid droplets and P-bodies |
| Q27490492 | Emerging role of microRNAs in liver diseases |
| Q37170593 | Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells |
| Q34473085 | Evolution of microRNAs and the diversification of species |
| Q34282491 | Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. |
| Q33701131 | Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection |
| Q52758318 | Extracellular Vesicle miRNA Detection Using Molecular Beacons. |
| Q37964746 | Failure of innate and adaptive immune responses in controlling hepatitis C virus infection |
| Q54326806 | Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. |
| Q38031228 | HCV and lymphoproliferation |
| Q37664059 | HCV drug discovery aimed at viral eradication |
| Q38603654 | HCV infection, IFN response and the coding and non-coding host cell genome |
| Q28384465 | HCV infection-associated hepatocellular carcinoma in humanized mice |
| Q35154024 | Hepatic HMOX1 expression positively correlates with Bach-1 and miR-122 in patients with HCV mono and HIV/HCV coinfection |
| Q90228670 | Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression |
| Q42203551 | Hepatic expression of miR-122, miR-126, miR-136 and miR-181a and their correlation to histopathological and clinical characteristics of patients with hepatitis C. |
| Q33726212 | Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C |
| Q36607449 | Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion |
| Q28283484 | Hepatitis C virus and hepatocarcinogenesis |
| Q53177200 | Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression. |
| Q37196517 | Hepatitis C virus infection, microRNA and liver disease progression |
| Q42996830 | Hepatitis C virus therapy: blocking the little microRNA helper of the virus. |
| Q37015738 | Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease |
| Q37772959 | Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. |
| Q37123557 | High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. |
| Q36827356 | Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome |
| Q35284740 | IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C. |
| Q34142463 | IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. |
| Q36840932 | Identification of miRNomes reveals ssc-miR-30d-R_1 as a potential therapeutic target for PRRS viral infection |
| Q38902559 | Immune regulation in chronic hepatitis C virus infection |
| Q42232134 | Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. |
| Q24654091 | In vitro characterization of a miR-122-sensitive double-helical switch element in the 5' region of hepatitis C virus RNA |
| Q37654502 | Individualization of chronic hepatitis C treatment according to the host characteristics |
| Q38107461 | Inflammation and liver tumorigenesis |
| Q34305346 | Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α. |
| Q34433087 | Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. |
| Q37799601 | Interferons and MicroRNAs |
| Q33599325 | Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C. |
| Q28534077 | Kinetics of miR-122 expression in the liver during acute HCV infection |
| Q37688134 | Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches |
| Q34635210 | Liver-specific microRNA-122: Biogenesis and function |
| Q42226193 | Longitudinal analysis of serum miR-122 in a rat model of Wilson's disease. |
| Q39439256 | Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity |
| Q34983626 | Mammalian MicroRNAs: Post-Transcriptional Gene Regulation in RNA Virus Infection and Therapeutic Applications. |
| Q37433774 | Mechanisms of HCV survival in the host |
| Q36349449 | Method for microRNA isolation from clinical serum samples |
| Q36923038 | MiR-122 in hepatic function and liver diseases |
| Q27008894 | MiR-122 in hepatitis B virus and hepatitis C virus dual infection |
| Q41812357 | MiR-199a/b-5p inhibits hepatocellular carcinoma progression by post-transcriptionally suppressing ROCK1 |
| Q39953406 | Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis |
| Q37060162 | Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. |
| Q42135669 | MicroRNA Expression in Selected Carcinomas of the Gastrointestinal Tract |
| Q34589553 | MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-α |
| Q42269945 | MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis. |
| Q64228210 | MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway |
| Q84598388 | MicroRNA-199a/b-3p: a new star in the liver microcosmos |
| Q37726449 | MicroRNA-mediated gene silencing |
| Q37393263 | MicroRNAs and Epithelial Immunity |
| Q34717904 | MicroRNAs and liver disease. |
| Q38163522 | MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma |
| Q47892086 | MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospects. |
| Q34585272 | MicroRNAs as biomarkers in rheumatic diseases. |
| Q28545051 | MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients |
| Q37613598 | MicroRNAs in Liver Disease: Bench to Bedside |
| Q37875000 | MicroRNAs in the midst of myeloid signal transduction. |
| Q27015778 | MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy |
| Q35606627 | MicroRNAs: Role in Hepatitis C Virus pathogenesis |
| Q37858630 | Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection |
| Q37863141 | Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? |
| Q36602293 | Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients |
| Q41748180 | Piecing together the key players of fibrosis in chronic hepatitis C: what roles do non-hepatic liver resident cell types play? |
| Q27014043 | Post-transcriptional regulation of interferons and their signaling pathways |
| Q34265451 | Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients |
| Q36759724 | Promotion of Hendra virus replication by microRNA 146a |
| Q37489877 | Prospects of RNAi and microRNA-based therapies for hepatitis C. |
| Q37856840 | RNAi and cellular miRNAs in infections by mammalian viruses |
| Q33887760 | Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C |
| Q37688816 | Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma |
| Q42768559 | Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. |
| Q42998004 | Reply to miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection |
| Q36811917 | Repressed induction of interferon-related microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. |
| Q42734199 | Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans |
| Q35111113 | Retinoic acid-inducible gene I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the very low density lipoprotein receptor |
| Q38202220 | Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. |
| Q38172567 | Roadmap of miR-122-related clinical application from bench to bedside |
| Q38335830 | Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site |
| Q46853359 | Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. |
| Q40246520 | Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. |
| Q35196062 | Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4 |
| Q34186933 | Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection |
| Q42287425 | Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy |
| Q36835537 | Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. |
| Q58715600 | Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection |
| Q42232743 | Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy |
| Q39177306 | Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication |
| Q34087743 | Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells |
| Q35261089 | Targeting microRNA-122 to Treat Hepatitis C Virus Infection |
| Q27491314 | Targeting viral infection by microRNA inhibition |
| Q57001209 | The Emerging Role of MicroRNAs in Hepatocellular Carcinoma |
| Q36969738 | The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study |
| Q37867509 | The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids? |
| Q39881002 | The Role of MicroRNAs in Response to Interferon Treatment of Chronic Hepatitis C patients |
| Q36416030 | The Type I IFN-Induced miRNA, miR-21 |
| Q36758996 | The effects of hepatitis C virus core protein on the expression of miR-122 in vitro |
| Q42981009 | The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin |
| Q38514365 | The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections |
| Q24628683 | The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice |
| Q36299753 | The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins |
| Q33622318 | The miRNAome of the postpartum dairy cow liver in negative energy balance |
| Q26995410 | The modulation of apoptosis by oncogenic viruses |
| Q38074417 | The not-so-neutral role of microRNAs in neutrophil biology. |
| Q42259914 | The role of microRNAs in hepatitis C virus RNA replication |
| Q35084134 | The role of nuclear factor κB in the interferon response |
| Q45056956 | The structure behind diversity: covariance networks in hepatitis C virus sequences are associated with treatment response |
| Q29615959 | Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection |
| Q40708778 | Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection |
| Q36624321 | Topographical effects on fiber-mediated microRNA delivery to control oligodendroglial precursor cells development. |
| Q33748950 | Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver |
| Q91151795 | Transcriptomic Analysis of mRNA-lncRNA-miRNA Interactions in Hepatocellular Carcinoma |
| Q33705481 | Traversing the RNA world |
| Q33723810 | Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma |
| Q37972773 | What's new in HCV genotype 2 treatment |
| Q38003338 | Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? |
| Q84867203 | [Molecular diagnostics for monitoring and predicting therapeutic effect in cancer] |
| Q90313762 | miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2 |
| Q38123745 | miR-122 promotion of the hepatitis C virus life cycle: sound in the silence |
| Q36129151 | miR-122 regulates hepatic lipid metabolism and tumor suppression |
| Q37059546 | miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. |
| Q34112056 | miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. |
| Q38092617 | miRNA-Based Therapeutic Strategies |
| Q52317101 | miRNAs regulate immune response and signaling during hepatitis C virus infection. |
| Q31141908 | microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection |
| Q24595141 | microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma |
| Q24620203 | microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity |
Search more.